108 related articles for article (PubMed ID: 9165547)
21. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
Westermann AM; Dubbelman R; Baars JP; Moolenaar WH; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2000; 46(1):57-62. PubMed ID: 10912579
[TBL] [Abstract][Full Text] [Related]
22. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A
J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081
[TBL] [Abstract][Full Text] [Related]
23. Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma.
Kerkhofs TM; Derijks LJ; Ettaieb H; den Hartigh J; Neef K; Gelderblom H; Guchelaar HJ; Haak HR
Ther Drug Monit; 2015 Feb; 37(1):58-65. PubMed ID: 24887633
[TBL] [Abstract][Full Text] [Related]
24. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
25. Cell surface binding and cellular internalization properties of suramin, a novel antineoplastic agent.
Stein CA; Khan TM; Khaled Z; Tonkinson JL
Clin Cancer Res; 1995 May; 1(5):509-17. PubMed ID: 9816010
[TBL] [Abstract][Full Text] [Related]
26. Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect.
La Rocca RV; Stein CA; Danesi R; Jamis-Dow CA; Weiss GH; Myers CE
J Clin Endocrinol Metab; 1990 Aug; 71(2):497-504. PubMed ID: 2380344
[TBL] [Abstract][Full Text] [Related]
27. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.
Lawrence JB; Conover CA; Haddad TC; Ingle JN; Reid JM; Ames MM; Suman VJ; Marks RS; Erlichman C; Hartmann LC
Clin Cancer Res; 1997 Oct; 3(10):1713-20. PubMed ID: 9815555
[TBL] [Abstract][Full Text] [Related]
29. Determination of suramin in clinical samples using HPLC.
Brandsteterová E; Chovancová V; Koza I; Mardiak J; Hal'ko J
Neoplasma; 1991; 38(4):425-32. PubMed ID: 1922574
[TBL] [Abstract][Full Text] [Related]
30. Toxicology and Carcinogenesis Studies of Furosemide (CAS No. 54-31-9) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1989 May; 356():1-190. PubMed ID: 12695785
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
Costa R; Wesolowski R; Raghavan D
BJU Int; 2011 Nov; 108(10):1546-54. PubMed ID: 21883840
[TBL] [Abstract][Full Text] [Related]
32. [The pharmacodynamics and pharmacokinetics of furosemide during ordinary life activities and during head-down tilt hypokinesia in a healthy subject].
Noskov VB; Goncharov IV; Kovachevich IV; Repenkova LG; Kodratenko SN; Starodubtsev AK
Eksp Klin Farmakol; 1998; 61(4):29-33. PubMed ID: 9783105
[TBL] [Abstract][Full Text] [Related]
33. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
Bassan R; Chiodini B; Zucchetti M; Lerede T; Cornelli PE; Cortelazzo S; Barbui T
Haematologica; 1998 Jan; 83(1):27-33. PubMed ID: 9542320
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Lee CK; Rowinsky EK; Li J; Giles F; Moore MJ; Hidalgo M; Capparelli E; Jolivet J; Baker SD
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2158-65. PubMed ID: 16609029
[TBL] [Abstract][Full Text] [Related]
35. Suramin's development: what did we learn?
Kaur M; Reed E; Sartor O; Dahut W; Figg WD
Invest New Drugs; 2002 May; 20(2):209-19. PubMed ID: 12099581
[TBL] [Abstract][Full Text] [Related]
36. Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one.
Tisdale JF; Figg WD; Reed E; McCall NA; Alkins BR; Horne MK
Am J Hematol; 1996 Feb; 51(2):152-7. PubMed ID: 8579057
[TBL] [Abstract][Full Text] [Related]
37. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
[TBL] [Abstract][Full Text] [Related]
38. Suramin in adrenocortical cancer: limited efficacy and serious toxicity.
Arlt W; Reincke M; Siekmann L; Winkelmann W; Allolio B
Clin Endocrinol (Oxf); 1994 Sep; 41(3):299-307. PubMed ID: 7955436
[TBL] [Abstract][Full Text] [Related]
39. Suramin: prototype of a new generation of antitumor compounds.
La Rocca RV; Stein CA; Myers CE
Cancer Cells; 1990 Apr; 2(4):106-15. PubMed ID: 2202382
[TBL] [Abstract][Full Text] [Related]
40. Adaptive control with feedback strategies for suramin dosing.
Cooper MR; Lieberman R; La Rocca RV; Gernt PR; Weinberger MS; Headlee DJ; Kohler DR; Goldspiel BR; Peck CC; Myers CE
Clin Pharmacol Ther; 1992 Jul; 52(1):11-23. PubMed ID: 1623689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
